Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.50 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28725284 | 0.94 | CYP3A4 (0.50) | CYP3A4GABBR2GABBR1GABRR1LPAR3 | |
| SCHEMBL28659304 | 0.89 | GABBR2 (0.47) | CYP3A4GABBR2GABBR1GABRR1TSHR | |
| SCHEMBL11514808 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL575182 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11421377 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL13725888 | 0.86 | LPAR3 (0.46) | CYP3A4GABBR2GABBR1GABRR1LPAR3 | |
| SCHEMBL11515024 | 0.85 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11564266 | 0.85 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL11040982 | 0.85 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL10832782 | 0.84 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7317046-B2 | Cyclic phosphazenes, process for preparing them, flame retardant containing them as active ingredient, and resin composition containing them and molded article therefrom | CHEMIPRO KASEI KAISHA, LIMITED (JP) | 2008-01-08 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20050159509-A1 | Varnish, shaped item, electrical insulating film, laminate, flame retardant slurry and process for producing flame retardant particles and varnish | ZEON CORPORATION (JP) | 2005-07-21 | — | — | US | disclosed |
| US-20040152910-A1 | Cyclic phosphazenes, process for preparing them, flame retardants containing the same as the active ingredient, and resin composition containing and molded articles containing the flame retardants | CHEMIPRO KASEI KAISHA, LIMITED (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-1403273-A1 | CYCLIC PHOSPHAZENES, PROCESS FOR PREPARING THEM, FLAME RETARDANTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT, AND RESIN COMPOSITIONS AND MOLDED ARTICLES CONTAINING THE FLAME RETARDANTS | Chemipro Kasei Kaisha, Limited (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152910-A1 | Cyclic phosphazenes, process for preparing them, flame retardants containing the same as the active ingredient, and resin composition containing and molded articles containing the flame retardants | PFAS, AFF1, PHOSPHO1 | CYP3A4 2438/4885GABBR2 2840/4885GABBR1 3002/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | CYP3A4 2660/4885GABBR2 4654/4885GABBR1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.